{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Dapagliflozin",
        "type": {
          "id": "2b8faf32-3325-4895-922a-2363dc9d8ed3",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "82113967-bf68-4ba7-8af1-237982286759",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Highly selective and reversible inhibitor of human renal SGLT2 for the treatment of chronic heart failure with reduced ejection fraction (HFrEF).",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "a34cb8bb-ec51-4126-a3ce-10680a471a20",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "6db3a4a1-bc9d-41f9-a885-b086fa86b2f7",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo tablets identical in size, color, smell, and taste to dapagliflozin.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Standard of Care Therapy",
        "type": {
          "id": "6495351c-fee8-4307-9c1f-e72017ecc485",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "d5da27e9-c6e6-4c94-9d48-bdba4d1f8203",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Regional standard of care for heart failure, including ACE inhibitors, ARBs, sacubitril/valsartan, beta-blockers, and MRAs."
      },
      {
        "id": "int_4",
        "name": "Diuretics",
        "type": {
          "id": "671f1dd0-f7e7-45e0-8814-c5955e745ab1",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "bb64e421-9221-4bb9-8349-216cbb455c72",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted and expected for volume control; doses may be titrated as clinically indicated."
      },
      {
        "id": "int_5",
        "name": "SGLT2 inhibitors (open-label)",
        "type": {
          "id": "57de1ef9-00a8-4506-a70a-6b22f042876f",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "2785225c-a485-4764-9ac2-203ca2aba583",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited in combination with IP; should be avoided during the course of the study."
      },
      {
        "id": "int_6",
        "name": "NSAIDs",
        "type": {
          "id": "33afa5e3-867b-47ad-85c2-14798996cc58",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "ad02071c-9deb-4979-b3dc-0e9f5d8bd874",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Use should be re-considered if unexpected acute decline in kidney function occurs."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Dapagliflozin tablets",
        "administrableDoseForm": {
          "id": "aee9617c-a0b8-4e11-8e08-c1c64bd2ad9f",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "add4fc2a-5f86-404d-bae2-f088d7da6ee9",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "cb187dc3-5e60-465f-bf06-67d11d58ecdc",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "10 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "AstraZeneca"
      },
      {
        "id": "prod_2",
        "name": "Dapagliflozin tablets",
        "administrableDoseForm": {
          "id": "681bf5a0-342b-4d8c-b177-1601cc9d47af",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "50b027d1-52ca-430f-ba4b-5f648a9dfede",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "ff15a221-6ca9-4821-bba0-4ae057dfa817",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "5 mg",
        "manufacturer": "AstraZeneca"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Dapagliflozin 10 mg daily",
        "instanceType": "Administration",
        "dose": "10 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Estimated mean treatment period of 24 months (event-driven study)"
      },
      {
        "id": "admin_2",
        "name": "Dapagliflozin 5 mg daily",
        "instanceType": "Administration",
        "dose": "5 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Temporary use when clinically indicated (e.g., volume depletion or renal concerns)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Dapagliflozin",
        "instanceType": "Substance",
        "description": "Sodium glucose co-transporter 2 (SGLT2) inhibitor"
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "Cardiac Resynchronization Therapy (CRT)",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      },
      {
        "id": "dev_2",
        "name": "Ventricular Assistance Device (VAD)",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      }
    ],
    "summary": {
      "interventionCount": 6,
      "productCount": 2,
      "deviceCount": 2
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Dapagliflozin",
        "role": "Investigational Product",
        "description": "Highly selective and reversible inhibitor of human renal SGLT2 for the treatment of chronic heart failure with reduced ejection fraction (HFrEF)."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo tablets identical in size, color, smell, and taste to dapagliflozin."
      },
      {
        "name": "Standard of Care Therapy",
        "role": "Background Therapy",
        "description": "Regional standard of care for heart failure, including ACE inhibitors, ARBs, sacubitril/valsartan, beta-blockers, and MRAs."
      },
      {
        "name": "Diuretics",
        "role": "Concomitant Medication",
        "description": "Permitted and expected for volume control; doses may be titrated as clinically indicated."
      },
      {
        "name": "SGLT2 inhibitors (open-label)",
        "role": "Concomitant Medication",
        "description": "Prohibited in combination with IP; should be avoided during the course of the study."
      },
      {
        "name": "NSAIDs",
        "role": "Concomitant Medication",
        "description": "Use should be re-considered if unexpected acute decline in kidney function occurs."
      }
    ],
    "products": [
      {
        "name": "Dapagliflozin tablets",
        "doseForm": "Tablet",
        "strength": "10 mg",
        "manufacturer": "AstraZeneca"
      },
      {
        "name": "Dapagliflozin tablets",
        "doseForm": "Tablet",
        "strength": "5 mg",
        "manufacturer": "AstraZeneca"
      }
    ],
    "substances": [
      {
        "name": "Dapagliflozin",
        "description": "Sodium glucose co-transporter 2 (SGLT2) inhibitor"
      }
    ],
    "administrations": [
      {
        "name": "Dapagliflozin 10 mg daily",
        "dose": "10 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Estimated mean treatment period of 24 months (event-driven study)"
      },
      {
        "name": "Dapagliflozin 5 mg daily",
        "dose": "5 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Temporary use when clinically indicated (e.g., volume depletion or renal concerns)"
      }
    ],
    "devices": [
      {
        "name": "Cardiac Resynchronization Therapy (CRT)",
        "manufacturer": "Not specified",
        "purpose": "Device therapy for heart failure management"
      },
      {
        "name": "Ventricular Assistance Device (VAD)",
        "manufacturer": "Not specified",
        "purpose": "Mechanical circulatory support (exclusion criteria if implanted prior to randomization)"
      }
    ]
  }
}